BEAT Quote, Financials, Valuation and Earnings

National Research Corp. has a net margin of -- compared to HeartBeam, Inc.'s net margin of 11.54%. HeartBeam, Inc.'s return on equity of -555.14% beat National Research Corp.'s return on equity of 61.55%.

HeartBeam, Inc. has a consensus price target of $4.33, signalling upside risk potential of 493.61%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that HeartBeam, Inc. has higher upside potential than National Research Corp., analysts believe HeartBeam, Inc. is more attractive than National Research Corp..

HeartBeam, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

HeartBeam, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 3.03% to investors and pays a quarterly dividend of $0.12 per share. HeartBeam, Inc. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HeartBeam, Inc. quarterly revenues are --, which are smaller than National Research Corp. quarterly revenues of $34.6M. HeartBeam, Inc.'s net income of -$5.3M is lower than National Research Corp.'s net income of $4M. Notably, HeartBeam, Inc.'s price-to-earnings ratio is -- while National Research Corp.'s PE ratio is 22.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HeartBeam, Inc. is -- versus 2.60x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

OneMedNet Corp. has a net margin of -- compared to HeartBeam, Inc.'s net margin of -418.64%. HeartBeam, Inc.'s return on equity of -555.14% beat OneMedNet Corp.'s return on equity of --.

HeartBeam, Inc. has a consensus price target of $4.33, signalling upside risk potential of 493.61%. On the other hand OneMedNet Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that HeartBeam, Inc. has higher upside potential than OneMedNet Corp., analysts believe HeartBeam, Inc. is more attractive than OneMedNet Corp..

HeartBeam, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OneMedNet Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HeartBeam, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OneMedNet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HeartBeam, Inc. pays -- of its earnings as a dividend. OneMedNet Corp. pays out -- of its earnings as a dividend.

HeartBeam, Inc. quarterly revenues are --, which are smaller than OneMedNet Corp. quarterly revenues of $177K. HeartBeam, Inc.'s net income of -$5.3M is lower than OneMedNet Corp.'s net income of -$741K. Notably, HeartBeam, Inc.'s price-to-earnings ratio is -- while OneMedNet Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HeartBeam, Inc. is -- versus 136.88x for OneMedNet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of -- compared to HeartBeam, Inc.'s net margin of -2156852.78%. HeartBeam, Inc.'s return on equity of -555.14% beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

HeartBeam, Inc. has a consensus price target of $4.33, signalling upside risk potential of 493.61%. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 956.34%. Given that Predictive Oncology, Inc. has higher upside potential than HeartBeam, Inc., analysts believe Predictive Oncology, Inc. is more attractive than HeartBeam, Inc..

HeartBeam, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

HeartBeam, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HeartBeam, Inc. pays -- of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend.

HeartBeam, Inc. quarterly revenues are --, which are smaller than Predictive Oncology, Inc. quarterly revenues of $3.6K. HeartBeam, Inc.'s net income of -$5.3M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, HeartBeam, Inc.'s price-to-earnings ratio is -- while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HeartBeam, Inc. is -- versus 13.06x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of -- compared to HeartBeam, Inc.'s net margin of 9.46%. HeartBeam, Inc.'s return on equity of -555.14% beat Spok Holdings, Inc.'s return on equity of 10.88%.

HeartBeam, Inc. has a consensus price target of $4.33, signalling upside risk potential of 493.61%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.29%. Given that HeartBeam, Inc. has higher upside potential than Spok Holdings, Inc., analysts believe HeartBeam, Inc. is more attractive than Spok Holdings, Inc..

HeartBeam, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

HeartBeam, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.6% to investors and pays a quarterly dividend of $0.31 per share. HeartBeam, Inc. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

HeartBeam, Inc. quarterly revenues are --, which are smaller than Spok Holdings, Inc. quarterly revenues of $33.9M. HeartBeam, Inc.'s net income of -$5.3M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, HeartBeam, Inc.'s price-to-earnings ratio is -- while Spok Holdings, Inc.'s PE ratio is 16.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HeartBeam, Inc. is -- versus 1.93x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.